PURPOSE: Inter-individual variations in treatment efficacy may be influenced by polymorphisms in DNA repair genes. We investigated the association of 3 functional polymorphisms in the nucleotide excision repair (NER) pathway with survival outcome of 95 patients with metastatic breast cancer (MBC) treated with DNA-damaging chemotherapy. METHODS: ERCC1 8092 C/A, ERCC2 Asp312Asn and ERCC2 Lys751Gln were determined using Taqman-based genotyping assays. Genotype associations with breast cancer-specific survival (BCSS) and progression-free survival (PFS) were evaluated using Kaplan-Meier estimates and hazard ratios calculated using Cox regression analysis. Tests for trend were conducted by calculating P-values for the HR coefficient in proportional hazards regression models. RESULTS: ERCC2 Lys751Gln was significantly associated with BCSS (median: 24.8 months for AA/AC combined and 14.2 months for CC, HR: 1.9 (95% CI 1.06-3.26)). Median BCSS decreased with increasing number of designated adverse genotypes for the 3 polymorphisms (P (trend) = 0.003). Risk estimates for PFS were nonsignificantly elevated and were significantly elevated for BCSS for patients with 2 (HR = 2.21, 95% CI: 1.04-4.72) or 3 (HR = 6.67, 95% CI: 2.19-20.29) adverse genotypes. In treatment subgroup analysis, risk estimates for BCSS were significantly elevated for patients with 3 adverse genotypes treated with cyclophosphamide, mitoxantrone and vinblastine (HR: 11.9, 95% CI 1.77-79.51) and P (trend) = 0.02 for increasing number of adverse genotypes. Risk of progression was significantly increased for patients with 1 adverse genotype treated with cyclophosphamide, mitoxantrone and carboplatin (HR: 3.5, 95% CI 1.19-10.6) and P (trend) = 0.02 for increasing number of adverse genotypes. CONCLUSION: Polymorphisms in NER pathway may impact survival outcome for patients with MBC following treatment with DNA-damaging chemotherapy. These results provide support for a polygenic pathway approach for assessing the prognostic and predictive potential of polymorphisms in treatment outcome.
PURPOSE: Inter-individual variations in treatment efficacy may be influenced by polymorphisms in DNA repair genes. We investigated the association of 3 functional polymorphisms in the nucleotide excision repair (NER) pathway with survival outcome of 95 patients with metastatic breast cancer (MBC) treated with DNA-damaging chemotherapy. METHODS:ERCC18092 C/A, ERCC2Asp312Asn and ERCC2Lys751Gln were determined using Taqman-based genotyping assays. Genotype associations with breast cancer-specific survival (BCSS) and progression-free survival (PFS) were evaluated using Kaplan-Meier estimates and hazard ratios calculated using Cox regression analysis. Tests for trend were conducted by calculating P-values for the HR coefficient in proportional hazards regression models. RESULTS:ERCC2Lys751Gln was significantly associated with BCSS (median: 24.8 months for AA/AC combined and 14.2 months for CC, HR: 1.9 (95% CI 1.06-3.26)). Median BCSS decreased with increasing number of designated adverse genotypes for the 3 polymorphisms (P (trend) = 0.003). Risk estimates for PFS were nonsignificantly elevated and were significantly elevated for BCSS for patients with 2 (HR = 2.21, 95% CI: 1.04-4.72) or 3 (HR = 6.67, 95% CI: 2.19-20.29) adverse genotypes. In treatment subgroup analysis, risk estimates for BCSS were significantly elevated for patients with 3 adverse genotypes treated with cyclophosphamide, mitoxantrone and vinblastine (HR: 11.9, 95% CI 1.77-79.51) and P (trend) = 0.02 for increasing number of adverse genotypes. Risk of progression was significantly increased for patients with 1 adverse genotype treated with cyclophosphamide, mitoxantrone and carboplatin (HR: 3.5, 95% CI 1.19-10.6) and P (trend) = 0.02 for increasing number of adverse genotypes. CONCLUSION: Polymorphisms in NER pathway may impact survival outcome for patients with MBC following treatment with DNA-damaging chemotherapy. These results provide support for a polygenic pathway approach for assessing the prognostic and predictive potential of polymorphisms in treatment outcome.
Authors: Penelope A Bradbury; Matthew H Kulke; Rebecca S Heist; Wei Zhou; Clement Ma; Wei Xu; Ariela L Marshall; Rihong Zhai; Susanne M Hooshmand; Kofi Asomaning; Li Su; Frances A Shepherd; Thomas J Lynch; John C Wain; David C Christiani; Geoffrey Liu Journal: Pharmacogenet Genomics Date: 2009-08 Impact factor: 2.089
Authors: Alessandra A Affatato; Kevin J Wolfe; Mirtha S Lopez; Csilla Hallberg; Marinel M Ammenheuser; Sherif Z Abdel-Rahman Journal: Environ Mol Mutagen Date: 2004 Impact factor: 3.216
Authors: Magdalena M Michalska; Dariusz Samulak; Hanna Romanowicz; Jan Bieńkiewicz; Maciej Sobkowski; Krzysztof Ciesielski; Beata Smolarz Journal: Tumour Biol Date: 2015-06-30
Authors: Shilong Zhong; Tomoko Nukui; Shama Buch; Brenda Diergaarde; Lisa A Weissfeld; Jennifer Grandis; Marjorie Romkes; Joel L Weissfeld Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-09-02 Impact factor: 4.254
Authors: Ailith Pirie; Qi Guo; Peter Kraft; Sander Canisius; Diana M Eccles; Nazneen Rahman; Heli Nevanlinna; Constance Chen; Sofia Khan; Jonathan Tyrer; Manjeet K Bolla; Qin Wang; Joe Dennis; Kyriaki Michailidou; Michael Lush; Alison M Dunning; Mitul Shah; Kamila Czene; Hatef Darabi; Mikael Eriksson; Dieter Lambrechts; Caroline Weltens; Karin Leunen; Chantal van Ongeval; Børge G Nordestgaard; Sune F Nielsen; Henrik Flyger; Anja Rudolph; Petra Seibold; Dieter Flesch-Janys; Carl Blomqvist; Kristiina Aittomäki; Rainer Fagerholm; Taru A Muranen; Janet E Olsen; Emily Hallberg; Celine Vachon; Julia A Knight; Gord Glendon; Anna Marie Mulligan; Annegien Broeks; Sten Cornelissen; Christopher A Haiman; Brian E Henderson; Frederick Schumacher; Loic Le Marchand; John L Hopper; Helen Tsimiklis; Carmel Apicella; Melissa C Southey; Simon S Cross; Malcolm Wr Reed; Graham G Giles; Roger L Milne; Catriona McLean; Robert Winqvist; Katri Pylkäs; Arja Jukkola-Vuorinen; Mervi Grip; Maartje J Hooning; Antoinette Hollestelle; John Wm Martens; Ans Mw van den Ouweland; Federick Marme; Andreas Schneeweiss; Rongxi Yang; Barbara Burwinkel; Jonine Figueroa; Stephen J Chanock; Jolanta Lissowska; Elinor J Sawyer; Ian Tomlinson; Michael J Kerin; Nicola Miller; Hermann Brenner; Katja Butterbach; Bernd Holleczek; Vesa Kataja; Veli-Matti Kosma; Jaana M Hartikainen; Jingmei Li; Judith S Brand; Keith Humphreys; Peter Devilee; Robert Aem Tollenaar; Caroline Seynaeve; Paolo Radice; Paolo Peterlongo; Siranoush Manoukian; Filomena Ficarazzi; Matthias W Beckmann; Alexander Hein; Arif B Ekici; Rosemary Balleine; Kelly-Anne Phillips; Javier Benitez; M Pilar Zamora; Jose Ignacio Arias Perez; Primitiva Menéndez; Anna Jakubowska; Jan Lubinski; Jacek Gronwald; Katarzyna Durda; Ute Hamann; Maria Kabisch; Hans Ulrich Ulmer; Thomas Rüdiger; Sara Margolin; Vessela Kristensen; Siljie Nord; D Gareth Evans; Jean Abraham; Helena Earl; Christopher J Poole; Louise Hiller; Janet A Dunn; Sarah Bowden; Rose Yang; Daniele Campa; W Ryan Diver; Susan M Gapstur; Mia M Gaudet; Susan Hankinson; Robert N Hoover; Anika Hüsing; Rudolf Kaaks; Mitchell J Machiela; Walter Willett; Myrto Barrdahl; Federico Canzian; Suet-Feung Chin; Carlos Caldas; David J Hunter; Sara Lindstrom; Montserrat Garcia-Closas; Fergus J Couch; Georgia Chenevix-Trench; Arto Mannermaa; Irene L Andrulis; Per Hall; Jenny Chang-Claude; Douglas F Easton; Stig E Bojesen; Angela Cox; Peter A Fasching; Paul Dp Pharoah; Marjanka K Schmidt Journal: Breast Cancer Res Date: 2015-04-22 Impact factor: 6.466
Authors: Shamik Das; Sarah K Bailey; Brandon J Metge; Ann Hanna; Dominique C Hinshaw; Mateus Mota; Andres Forero-Torres; John C Chatham; Rajeev S Samant; Lalita A Shevde Journal: Lab Invest Date: 2018-11-12 Impact factor: 5.662